BioHedge Weekly
13D/13G filings from 18 institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform with clinical trials, SEC filings, and hedge fund positioning, linked by company.
Weekly Delivery
Get next week's BioHedge Weekly by email
One email per week. We follow up on coverage that's relevant to you.
or email [email protected]
Weekly Filing Volume
Filings This Week
| Fund / Company | Ownership & Type |
|---|---|
Baker Brothers Advisors ABCELLERA BIOLOGICS INC (ABCL) | 10.8% 13G/A [SEC] |
EcoR1 Capital ATARA BIOTHERAPEUTICS INC (ATRA) | 17.4% +7.5 13G/A [SEC] |
5AM Ventures Rallybio Corp (RLYB) | 0.0% 13D/A [SEC] |
OrbiMed Traws Pharma, Inc. (TRAW)
Investment | 11.9% -8.0 13D/A [SEC] The Reporting Persons intend to review their investment in TRAW and may acquire or dispose of shares based on various factors, including the Issuer's business, financial condition, and market conditions. They have not formulated any plans for extraordinary corporate transactions, changes to the board or management, or material changes to the Issuer's capitalization or business structure. |
MPM BioImpact Werewolf Therapeutics, Inc. (HOWL) | 5.4% -1.5 13D/A [SEC] |
Perceptive Advisors TRINITY BIOTECH (TRIB)
Financing
Warrants | 9.9% 13D/A [SEC] Perceptive Advisors participated in an amendment to the Sixth Amended and Restated Credit Agreement, providing an additional $2.5 million term loan to Trinity Biotech. The Convertible Note was also amended to increase the convertible indebtedness from $60,000,000 to $72,500,000 and reduce the minimum conversion price from $1.03 to $0.5061 per ADS. Agreements · The Third Amendment provided a limited waiver for the borrower's non-compliance with certain financial covenants and an additional $2.5 million term loan. The Amended and Restated Note increased the aggregate convertible indebtedness to $72,500,000 and reduced the minimum conversion price to $0.5061 per ADS. |
Fairmount Funds Management LLC Oruka Therapeutics, Inc. (ORKA)
Disposition
Lock Up | 20.0% 13D/A [SEC] Agreements · In connection with Oruka Therapeutics' public offering, the Reporting Persons entered into a lock-up agreement with the underwriters, agreeing not to sell Company securities for 45 days from the underwriting agreement date without Leerink Partners' consent. The Reporting Persons did not participate in the offering. |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses more than 5% ownership in a company for the first time.
We track 18 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.